Edesa Biotech Inc expected to post a loss of 43  cents a share - Earnings Preview

Edesa Biotech

09/08/2022 17:31

* Edesa Biotech Inc  EDSA.OQ   EDSA.O  is expected to show
no
change in quarterly revenue when it reports  results on August
11 (estimated). 
    * ​Refinitiv's mean analyst estimate for Edesa Biotech Inc
is for
a loss of 43 cents per share. For the same quarter last year,
the company reported a loss of 36 cents per share.
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Edesa
Biotech Inc
is $16​, above​ its last closing price of $2.33. ​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Mar. 31 2022  -0.34       -0.37      -0.33     Beat    10
 Dec. 31 2022  -0.40       -0.40      -0.33     Beat    17.5
 Sep. 30 2021  -0.41       -0.37      -0.27     Beat    26.4​
 Jun. 30 2021  -0.32       -0.32      -0.36     Missed  -12.5
 ​​Mar.        -0.29       -0.29      -0.81     Missed  -174.6
 31 2021                                                
 Dec. 31 2020  -0.19       -0.19      -0.26     Missed  -36.8​
 Sep. 30 2020  -0.21       -0.20      -0.22     Missed  -7.3
 Jun. 30 2020  -0.23       -0.20      -0.20     Met     2.4
 This summary was machine generated August 9 at 16:31 GMT.  All
figures in US dollars  unless otherwise stated